Comparative efficacy and safety of blood pressure-lowering agents in adults with diabetes and kidney disease: a network meta-analysis (Q38502138)

3 September 2017

0 references

1 reference

title

Comparative efficacy and safety of blood pressure-lowering agents in adults with diabetes and kidney disease: a network meta-analysis (English)

1 reference

3 September 2017

1 reference

1 reference

1

Suetonia C Palmer

1 reference

3 September 2017

Jonathan C Craig

4

1 reference

3 September 2017

Marcello Tonelli

5

1 reference

3 September 2017

Georgia Salanti

6

1 reference

3 September 2017

Natasha Wiebe

7

1 reference

3 September 2017

8

Marinella Ruospo

1 reference

3 September 2017

10

Giovanni F M Strippoli

1 reference

3 September 2017

3

Eliano Navarese

1 reference

3 September 2017

Dimitris Mavridis

2

1 reference

3 September 2017

David C Wheeler

series ordinal

9

1 reference

3 September 2017

language of work or name

English

0 references

publication date

1 May 2015

1 reference

3 September 2017

1 reference

3 September 2017

volume

385

1 reference

3 September 2017

issue

9982

1 reference

3 September 2017

page(s)

2047-2056

1 reference

Global prevalence of diabetes: estimates for the year 2000 and projections for 2030

3 September 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2962459-4

7 January 2021

Nephropathy in patients with type 2 diabetes mellitus

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2962459-4

7 January 2021

Chronic kidney disease and the risk for cardiovascular disease, renal replacement, and death in the United States Medicare population, 1998 to 1999

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2962459-4

7 January 2021

Incidence of treatment for end-stage renal disease among individuals with diabetes in the U.S. continues to decline

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2962459-4

7 January 2021

Effects of angiotensin converting enzyme inhibitors and angiotensin II receptor antagonists on mortality and renal outcomes in diabetic nephropathy: systematic review

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2962459-4

7 January 2021

Chapter 4: Blood pressure management in CKD ND patients with diabetes mellitus

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2962459-4

7 January 2021

2014 evidence-based guideline for the management of high blood pressure in adults: report from the panel members appointed to the Eighth Joint National Committee (JNC 8)

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2962459-4

7 January 2021

Combined angiotensin inhibition for the treatment of diabetic nephropathy

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2962459-4

7 January 2021

Renal outcomes with telmisartan, ramipril, or both, in people at high vascular risk (the ONTARGET study): a multicentre, randomised, double-blind, controlled trial.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2962459-4

7 January 2021

ONTARGET still OFF-TARGET?

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2962459-4

7 January 2021

Comparative effectiveness of renin-angiotensin system blockers and other antihypertensive drugs in patients with diabetes: systematic review and bayesian network meta-analysis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2962459-4

7 January 2021

Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2962459-4

7 January 2021

Meta-analysis in clinical trials

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2962459-4

7 January 2021

Indirect and mixed-treatment comparison, network, or multiple-treatments meta-analysis: many names, many benefits, many concerns for the next generation evidence synthesis tool

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2962459-4

7 January 2021

Predicting the extent of heterogeneity in meta-analysis, using empirical data from the Cochrane Database of Systematic Reviews

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2962459-4

7 January 2021

A case study of multiple-treatments meta-analysis demonstrates that covariates should be considered

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2962459-4

7 January 2021

Evaluation of inconsistency in networks of interventions

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2962459-4

7 January 2021

Consistency and inconsistency in network meta-analysis: concepts and models for multi-arm studies

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2962459-4

7 January 2021

Graphical methods and numerical summaries for presenting results from multiple-treatment meta-analysis: an overview and tutorial

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2962459-4

7 January 2021

Consistency and inconsistency in network meta-analysis: model estimation using multivariate meta-regression

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2962459-4

7 January 2021

Graphical tools for network meta-analysis in STATA.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2962459-4

7 January 2021

A new era for the treatment of hyperkalemia?

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2962459-4

7 January 2021

Sodium zirconium cyclosilicate in hyperkalemia

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2962459-4

7 January 2021

Patiromer in patients with kidney disease and hyperkalemia receiving RAAS inhibitors

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2962459-4

7 January 2021

The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. The Collaborative Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2962459-4

7 January 2021

Avosentan for overt diabetic nephropathy

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2962459-4

7 January 2021

Angiotensin-converting enzyme inhibitors, angiotensin receptor blockers and combined therapy in patients with micro- and macroalbuminuria and other cardiovascular risk factors: a systematic review of randomized controlled trials

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2962459-4

7 January 2021

10.1016/S0140-6736(14)62459-4

Identifiers

DOI

1 reference

3 September 2017

1 reference